NCT01171690View on ClinicalTrials.gov

Teriparatide for Postsurgical Hypoparathyroidism

PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Hypoparathyroidism Post-surgical
Interventions
DRUG

Teriparatide

The dose of teriparatide will be 20 mcg twice daily for the first week and 20 mcg daily for the second week. If hypocalcemia recurs after 2nd week, teriparatide will be continued for a 3rd week and then discontinued.

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER